Clinical Trial Search

Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale

Primary: Alteration of Microbiota, Alteration of T Cell Function/Activation — 4; 10; 2; 0 participants

Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2

Primary: Percentage of CD27+ Switched Memory B Cells at Week 12 — 13.2; 13.8 Percentage of B Cells — p=0.3

Primary: Percentage of Participants Achieving American College of Rheumatology Score 20 Percent (ACR20) Response — 63.46; 76.15 Percentage of participants

Primary: 12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score — 11.4 units on a scale — p=<0.01

Primary: Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12 — 21.2; 33.0 percentage of participants — p=0.055

Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale

Primary: RADAI Disease Activity Score — -0.4; 0.1 units on a scale — p=0.04

Primary: Number of Subjects With Lipids Checked (Available Now Through National Laboratory Chain) or That Reported Having Their Lipids Checked by Their 1-week or 3-month Visit…

Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants

Primary: Metabolic Syndrome Severity Z-score (MSSc) — -1.89; -1.82; -3.23; -3.49 Z-score (unitless) — p=<0.05

Primary: CDAI Score — 36.06 score on a scale

Primary: Clinical Disease Activity Index (CDAI) Remission (≤2.8) at Both Week 20 and Week 24 — 18.8; 6.1 percentage of subjects

Primary: Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12 — 106; 59 participants — p=<0.001

Primary: Disease Activity — 3.38; 3.62 score on a scale

Primary: Proportion of Patients Who Met the ACR20 Responder Index Criteria — 28.57; 35.06; 37.75; 38.57 Proportion of Patients — p=<0.001

Primary: American College of Rheumatology 20% (ACR20) Response Rate at Week 12 — 45.1; 58.0; 60.0; 54.0 percentage of participants

Primary: Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) by American Rheumatism Association (ARA) Criteria and/or Discontinued Due to Lack of Efficacy — 12…

Primary: IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells of RA Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA. — 0.700; 1.330; 0.777…

Primary: Event Rate for a Cardiovascular Composite of Incident Myocardial Infarction, Stroke, or Heart Failure — 10.62; 8.13 Events per 1000 person years

Primary: Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10 — 49.7 Percentage

Primary: Evaluation of Disease Duration: Time From Diagnosis to Disease-Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis — 11.7177 Months

Primary: Change in VO2 Max, Maximum Oxygen Uptake in ml/Min/kg is the Standard Index of Cardio-respiratory Fitness — 3.82; -0.44 ml/min/kg — p=0.002

Primary: Hospital Anxiety and Depression Scale (HADS) — 107; 46; 20; 27 participants

Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 participants

Primary: Slow Wave Sleep — 82.6; 67.3 Minutes

Primary: Number of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response (20% Improvement) — 18; 8 Participants — p=0.0352

Primary: Percentage of Adverse Events (AEs) — 55.0; 70.0; 57.9 Percentage of participant with AEs

Primary: Percentage of Participants Achieving DAS28 Remission. — 6; 6 Participants — p=0.530